Business Context and Reporting Period
Company: Nephros, Inc. (NEPH)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Nephros is a commercial-stage company developing and selling high-performance water filtration solutions for medical and commercial markets. Medical products (ultrafilters) target hospitals and dialysis centers to prevent waterborne infections. Commercial products target food service, hospitality, and convenience stores to improve water quality. The company relies on third-party manufacturers, primarily Medica S.p.A. in Italy, for its proprietary filter materials.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Total Net Revenues | $14,162 | $14,238 |
| Gross Margin | $8,723 | $8,405 |
| Gross Margin % | 62% | 59% |
| Operating Income (Loss) | $6 | $(1,593) |
| Net Income (Loss) | $74 | $(1,575) |
| Cash and Cash Equivalents | $3,760 | $4,307 |
| Working Capital | $6,736 | $6,292 |
| Accumulated Deficit | $(144,332) | $(144,406) |
Debt & Liquidity: Total liabilities were $2.6 million, primarily consisting of lease liabilities ($1.4 million). The company had no long-term debt outstanding as of December 31, 2024, having paid off its secured note in 2023. Management believes current cash balances are sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Profitability Milestone: 2024 marked the company's first profitable year in its history, reporting net income of $74,000 compared to a net loss of $1.6 million in 2023.
- Revenue Decline: Total net revenues decreased 1% to $14.2 million. This was driven by a significant drop in "emergency response" orders (reactive filtration for pathogen outbreaks) which were unusually high in 2023. This decline was partially offset by a 9% increase in programmatic/recurring sales.
- Margin Expansion: Gross margin improved by 3 percentage points to 62%, attributed to more favorable terms with the company's largest supplier.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 14% ($1.2 million), primarily due to reduced stock-based compensation, bonuses, and commissions.
- Cash Flow: Net cash used in operating activities was $0.5 million in 2024, a reversal from the $0.8 million provided by operations in 2023. The 2024 usage was driven by increases in inventory and accounts receivable.
Guidance, Outlook, Risks, and Unusual Items
Outlook & Strategy: Management expects to continue focusing on growth in sales and tight expense management. The company is expanding distribution in the commercial market following the termination of its exclusive relationship with Donastar LLC in September 2024. While Donastar remains a non-exclusive distributor, Nephros is pursuing other national accounts to drive step-change revenue increases.
Key Risks:
- Supplier Concentration: The company relies on a single source supplier, Medica S.p.A., for proprietary filter material. A new agreement extends the term to 2028 but includes minimum annual purchase obligations (ranging from €4.2M to €5.75M). Failure to meet these could result in termination.
- Revenue Volatility: A portion of revenue is derived from unpredictable emergency response orders related to waterborne pathogen outbreaks.
- Liquidity: Despite 2024 profitability, the company has an accumulated deficit of $144.3 million and negative operating cash flow. Continued capital may be required if revenue growth does not materialize.
- Regulatory: Products are subject to FDA regulation (Class II devices). Non-compliance could lead to enforcement actions or recalls.
Unusual Items: The company dissolved its subsidiary, Specialty Renal Products (SRP), in April 2023. SRP's remaining assets were assigned to Nephros to satisfy a $1.5 million loan, resulting in no distribution to SRP stockholders.
Investor Verification Checklist
- Supplier Dependency: Verify the status of the License and Supply Agreement with Medica S.p.A. and the company's ability to meet the 2025 minimum purchase commitment of €4.6 million.
- Commercial Distribution: Assess the progress of new distributor relationships following the end of the exclusive agreement with Donastar LLC.
- Cash Burn Rate: Monitor operating cash flow trends, as the company returned to negative operating cash flow in 2024 despite net income.
- Customer Concentration: Note that Customer A accounted for 25% of 2024 revenue and 13% of accounts receivable.
- Stock Volatility: Review the trading range of the common stock ($0.95 to $4.04 over the last two years) and the potential for dilution from outstanding options (approx. 1.2 million shares).